VEGFA and neoplasm: Apatinib combined with SCH772984 exhibited a greater inhibitory effect on tumor growth of oral squamous cell carcinoma in vivo, which revealed that inhibition of ERK promoted the anticancer efficiency of apatinib in vivo.284 VEGF inhibitors, including ONC201, cabozantinib (XL-184), linifanib (ABT-869), sunitinib, motesanib, pazopanib, axitinib (AG-013736), and PTK787/ZK 222584, all had promising effects in the HNC model.285–289